v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2025
Dec. 31, 2024
 [1]
Current Assets:    
Cash and cash equivalents $ 2,374,229 $ 34,085
Prepaid expenses 479,775 11,454
Total Current Assets 2,854,004 45,539
Non-Current Assets:    
Deferred equity issuance costs 193,876
Total Assets 2,854,004 239,415
Current Liabilities:    
Accounts payable- trade 327,057 1,361,081
Accrued expenses 781,683 1,049,910
Convertible notes payable, net of debt issuance costs and discounts 1,248,708
Derivative liability arising from convertible notes payable 544,957
Accrued interest 134,875
Total Current Liabilities 1,108,740 4,339,531
Total Liabilities 1,108,740 4,339,531
Commitments and contingencies (Note 9)
Stockholders' Equity (Deficit):    
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024
Common stock, $0.0001 par value, 50,000,000 shares authorized, 8,401,481 shares issued and outstanding as of March 31, 2025 and 3,249,999 shares issued and outstanding as of December 31, 2024 840 325
Additional paid-in capital 6,471,740 23,791
Accumulated deficit (4,727,316) (4,124,232)
Total Stockholders' Equity (Deficit) 1,745,264 (4,100,116)
Total Liabilities and Stockholders' Equity (Deficit) $ 2,854,004 $ 239,415
[1] The number of shares and per share value of the Company’s common stock have been retroactively recast to reflect the exchange ratio pursuant to the Merger.

Source

10-Q PDF XBRL Zip